How does antifungal pharmacology differ for mucormycosis versus aspergillosis?

Russell E. Lewis, Olivier Lortholary, Brad Spellberg, Emmanuel Roilides, Dimitrios P. Kontoyiannis, Thomas J. Walsh

Research output: Contribution to journalArticlepeer-review

Abstract

Over the last decade, advances in diagnostic systems and the introduction of new antifungal agents have significantly improved outcomes in immunocompromised patients who develop invasive aspergillosis. However, mortality rates remain relatively unchanged for less common, but highly aggressive, mold infections such as mucormycosis. Recent genome sequencing of Rhizopus oryzae revealed evidence of a whole-genome duplication event during the evolution of this pathogen. Consequently, R. oryzae has a 2- to 10-fold enrichment in gene families associated with ergosterol and cell wall biosynthesis, cell growth, iron uptake, and known fungal virulence factors compared with sequenced Aspergillus fumigatus strains. This genetic plasticity may explain the remarkable capability of this pathogen for rapid growth in hostile environments, such as the inflammatory milieu, as well as its relative resistance to multiple antifungal classes. Herein, we examine how pharmacological aspects of treating mucormycosis may differ from those of the more commonly encountered invasive aspergillosis.

Original languageEnglish (US)
Pages (from-to)S67-S72
JournalClinical Infectious Diseases
Volume54
Issue numberSUPPL. 1
DOIs
StatePublished - Feb 1 2012

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'How does antifungal pharmacology differ for mucormycosis versus aspergillosis?'. Together they form a unique fingerprint.

Cite this